



# National Tuberculosis Research Programme

Private Bag X385 • 1 Soutpansberg Road • Pretoria 0001 • South Africa  
Tel: +27.12.339 8547 • Fax: +27.12.325 5970  
E-mail: bernard.fourie@mrc.ac.za

15 May 2001

To whom it may concern

MEDICAL RESEARCH  
COUNCIL

MEDIJSE  
NAVORSINGSRAAD

UMKHANDLU  
WOKUCWANINGA  
NGEZOKWELAPHA

LEKGOTLA LA  
PHUPUTSO  
HO TSA KALAFU

## BIOAVAILABILITY / BIOEQUIVALENCE STUDY

We hereby confirm that the following study was conducted on behalf of Novartis South Africa (Pty) Ltd as part of a joint venture between the National Tuberculosis Research Programme of the Medical Research Council of South Africa and the Department of Pharmacology at the University of Cape Town, and in conjunction with the World Health Organisation (WHO) Collaborating Centre for Drug Policy which is based in the pharmacology department. International standards for bioavailability testing were followed, and the following report was issued:

"Bioavailability and bioequivalence of Rifampicin and Isoniazid as a single dose in a fixed dose formulation Rimactazid 150/75 compared to equivalent doses of single reference preparations of the two drugs. Study report dated February 2000"

The above joint venture was approved by the Global Tuberculosis Programme of the WHO for the determination of bioavailability and bioequivalence of fixed-dose combination products for the treatment of tuberculosis.

Yours faithfully

Dr P B Fourie  
Director

### Branch Office

PO Box 19070 • Tygerberg 7505 • Cape Town • South Africa • Tel: +27.21.938 0311 • Fax: +27.21.938 0463  
King George V Hospital • PO Box 19494 • Dormerton 4015 • Durban • South Africa • Tel: +27.31.208 7121 • Fax: +27.31.208 6053